68 results about "Plasma samples" patented technology

A plasma digital marker mining and disease classification device comprises a plasma sample spectrum acquisition module used for determining a digital marker sorting cluster in a plurality of plasma samples; the plasma candidate digital marker selection module is used for iterating plasma spectrum samples in the initial disease classification device based on the digital marker sorting cluster to obtain a plasma candidate digital marker cluster; the pathogenic protein digital marker cluster acquisition module is used for acquiring pathogenic protein digital marker clusters corresponding to spectral absorption peaks of various related pathogenic proteins; the plasma digital marker mining module is used for determining an intersection of the plasma candidate digital marker cluster and the pathogenic protein digital marker cluster as a plasma digital marker; and the disease classification device construction module is used for training a disease classification device according to the plasma digital markers to obtain a trained disease classification device. By adopting the technical scheme, a disease classification device capable of accurately distinguishing MCI patients can be constructed.

The invention relates to the technical field of plasma concentration monitoring methods, in particular to a method for rapidly detecting the content of tacrolimus in plasma through paper spray mass spectrometry. The method provided by the invention comprises the following steps: adding a to-be-detected plasma sample into a precipitation solution, vortex, taking supernate, and dropwise adding the supernate onto a paper base; spraying voltage is applied to the paper base, the paper base generates electrospray, and the electrospray enters a mass spectrometer for detection; preparing a gradient matrix matched tacrolimus standard solution, replacing the to-be-detected plasma sample with the gradient matrix matched tacrolimus standard solution, repeating the operation, recording a detection result, and drawing a standard curve by taking the matrix matched tacrolimus concentration as an abscissa and taking peak area data acquired by a mass spectrometer as an ordinate; and comparing the recorded detection result with the drawn standard curve, and quantitatively analyzing the content of tacrolimus in the to-be-detected plasma sample. The method disclosed by the invention is simple to operate and high in analysis speed, has relatively good precision and accuracy and also has high sensitivity and high selectivity.

The current application reveals a method, apparatus, device, and storage medium for detecting micro residual lesions, falling within the domain of medical detection technology. This method is based on differentiated deep whole-exome / targeted drug sequencing and tissue-blood cell-plasma co-capture technology, and 100,000× ultra-high depth personalized / high evidence hotspot combination panel sequencing to evaluate tiny residual lesions and tumor evolution / second primary in plasma samples. It resolves the challenges of existing techniques, such as elevated tissue detection thresholds, restricted tracking locations, inadequate detection sensitivity and precision, or elevated costs when ctDNA concentrations in the bloodstream are minimal. Furthermore, it surmounts the challenge of simultaneously achieving personalized tracking detection and monitoring tumor evolution or second / primary detection. It markedly boosts the precision of forecasting the likelihood of recurrence following patient therapy within a restricted budget.

The invention provides a non-invasive fetal trisomy 21 syndrome prenatal screening kit based on digital PCR, and relates to the technical field of fetal trisomy 21 syndrome screening, according to a method for enriching fetal cfDNA in pregnant woman plasma, SPRIselect magnetic beads with low enrichment multiple and silicon hydroxyl magnetic beads are combined for use, and under a certain dosage, the recovery rate of fetal cfDNA short fragments reaches 95%; according to the provided multiple system construction method, positive gDNA and negative gDNA are obtained on the basis of a 21 trisomy positive cell line and a 21 trisomy negative cell line, low-proportion reference substances are prepared and used, internal reference sites and detection sites which are high in detection capacity and stable in detection performance are screened from the beginning, and compared with existing multiple system establishment and verification through direct use of pregnant woman plasma samples, the multiple system construction method has the advantages that the detection efficiency is high, and the detection cost is low. The to-be-detected sample with lower fetal cfDNA content can be stably detected.

The invention discloses a disease risk assessment method and screening device based on a multi-group student physical collaborative digital network, and relates to the field of intelligent medical detection. In order to solve the defect that multi-omics-level system collaborative analysis and robust risk assessment are difficult to realize in the prior art, the technical scheme provided by the invention is as follows: acquiring a plasma sample, acquiring a spectral signal by adopting an attenuated total reflection Fourier transform infrared spectrum, and establishing a plasma spectrum digital information space; the method comprises the following steps: constructing a biological collaborative digital network containing four nodes of protein, lipid, saccharides and nucleic acid based on pathophysiology priori knowledge, and defining node strength, edge weight and network collaborative efficiency; a health baseline configuration file is established by using a health sample, a standardized deviation score of a to-be-tested sample is calculated, a comprehensive risk score is obtained, a disease screening result is output in combination with a machine learning model, and digital evaluation of multi-omics collaborative characteristics is realized. The method is suitable for non-invasive rapid screening and risk assessment work of neurodegenerative diseases and mental diseases.

The invention relates to a biomarker-based near infrared spectrum characteristic wave band screening and pan cancer grading detection system and a working method thereof, and the working method comprises the following steps: a spectrum collection unit collects the near infrared spectrum of a to-be-detected plasma sample to obtain spectrum data; a spectrum abnormal value eliminating unit eliminates abnormal values; the clinical biochemical data abnormal value eliminating unit is used for eliminating abnormal values of the biochemical detection data; selecting a sample set division method and a division proportion; the spectrum pretreatment unit is used for pretreating a near infrared spectrum of a to-be-detected plasma sample; the spectral characteristic wave band screening unit screens spectral characteristic wave bands in combination with clinical biochemical indexes and near infrared spectrums, so that the accuracy of pan cancer recognition is improved; and the data analysis unit performs qualitative discriminant analysis on the near infrared spectrum data, constructs an accurate cancer primary detection model and an accurate cancer accurate detection model, preliminarily identifies cancers and finely screens esophageal squamous cell carcinoma, gastric cancer, colorectal cancer and lung cancer samples. The method has good practical application and reference value for large-scale screening of cancers.

The present invention relates to a ctDNA-based solid tumor MRD detection method, detection system, and computer-readable medium, and belongs to the technical field of tumor gene detection. The present invention proposes a method for qualitatively characterizing plasma sample MRD based on tissue baseline mutation sites during dynamic plasma testing. This method calculates the background error rate of single-base mutations, simulates mutation readings based on this error rate, and compares them with the actual observed mutation readings. The number of times the simulated mutation readings are greater than the actual observed mutation readings is statistically analyzed. The p-value of the sample ctDNA positive is calculated based on multiple simulation results at the mutation site.

The invention belongs to the technical field of chemical screening, and particularly relates to a systematic screening method for rubber-related chemicals in a plasma sample, which comprises the following steps: S1, taking the plasma sample, adding a mixed extraction solvent, extracting, centrifugally layering, collecting supernate, repeatedly extracting, merging the supernate, concentrating, and freezing to obtain a rubber-related chemical sample; centrifuging again, adding an isotope internal standard, and carrying out data dependence acquisition in a positive and negative ion analysis mode by adopting liquid chromatography-tandem high-resolution mass spectrometry. According to the invention, the comprehensive coverage type monitoring of 1300-1500 RDCs in the plasma sample is realized. By means of combination of a positive and negative ion double analysis mode and data dependence acquisition, the detection range and the signal response stability of the RDCs with different polarities are effectively considered, and the technical problem that in the prior art, the composite effect generated by coexistence of multiple RDCs is ignored is solved.

The invention discloses a preparation method of a blood coagulation factor quality control product. The preparation method comprises the following steps: treating mixed plasma of multiple persons by using a physical and chemical method; and mixing the multi-person mixed plasma with the factor diluent according to a certain proportion to prepare the blood coagulation routine item quality control product with different blood coagulation routine item contents at different concentration levels, subpackaging, and storing in an ultra-low temperature refrigerator at-80 DEG C to obtain the blood coagulation routine item quality control product. The blood coagulation routine item quality control product prepared by the invention is good in product uniformity, stability and frozen product remelting stability, can replace commercial products to be used for quality control of blood coagulation routine item detection, and is beneficial to reducing the detection cost and improving the blood coagulation routine item detection capability.

The present application relates to the field of bioinformatics, and specifically provides a lung cancer early screening model construction and application based on FDEM / FDBM feature extraction from LP-WGS sequencing data and PCC system noise reduction. By performing low-depth whole-genome sequencing of plasma sample cfDNA, high-throughput sequencing of lung cancer and healthy human cfDNA, extracting new features from the sequencing results, and using the PCC (Principal Component Correction) method to reduce background noise of the new features to improve the signal-to-noise ratio of cancer signals, a highly sensitive machine learning model for distinguishing lung cancer from healthy people is constructed, and ultimately achieving high-precision identification of lung cancer patients.

The application discloses a combined filter for separating plasma from whole blood, comprising a whole blood sample adding chamber, a first combined filter membrane, an intermediate chamber, a second combined filter membrane and a plasma collecting chamber arranged in sequence along a filtering direction of a whole blood sample flow; and the whole blood sample is filtered multiple times through the first combined filter membrane and the second combined filter membrane to obtain a plasma sample. The application further provides a combined filter device and a method for separating plasma from whole blood. The combined filter provided by the application can further improve the recovery rate, recovery quality and recovery efficiency of the whole blood separation plasma, and meets the demand of in-vitro diagnosis on the pretreatment of the whole blood sample.

This invention relates to the field of medical technology, specifically to a method for preoperative risk assessment and prediction in liver transplant patients with hepatocellular carcinoma, comprising the following steps: Sample collection: selecting plasma samples and corresponding clinicopathological information from liver transplant recipients of hepatocellular carcinoma, and clarifying the inclusion and exclusion criteria for samples; Plasma cell-free DNA extraction and whole-genome sequencing: extracting and quality-controlling cell-free DNA from the plasma samples collected in step S1, constructing a sequencing library, and performing low-coverage whole-genome sequencing. This invention utilizes plasma-extracted cfDNA for whole-genome sequencing, combined with clinical testing information, to construct a preoperative risk assessment and prediction model for postoperative recurrence in liver transplant recipients of hepatocellular carcinoma based on non-invasive testing. This model can be used to predict the probability of recurrence-free survival before liver transplantation. The model derivation cohort integrates clinical records and circulating tumor DNA data for preoperative recurrence risk prediction.

The invention provides methods for simultaneously enriching multiple target regions of interest in one reaction volume, from cell-free DNA isolated from a blood or plasma sample, followed by high-thought sequencing and sequence read analysis. The invention also provides library of target-specific oligonucleotide primers or probes for the multiplexed target enrichment.

The invention relates to a primer probe set for HBV (hepatitis B virus) in-vitro diagnosis, which comprises an internal standard primer probe set and a target primer probe set which are amplified in the same environment, and the internal standard primer probe set and the target primer probe set are configured as follows: the difference between the target probe and the internal standard probe is not more than 5 DEG C according to the fusion degree; the melting temperature of the probe of the internal standard is 5-10 DEG C higher than the melting temperature of the upstream and downstream primers of the internal standard; the probe melting temperature of the target is set to be 5-10 DEG C higher than the melting temperature of upstream and downstream primers of the target. According to the technical scheme, through three-dimensional technology coupling of melting temperature cooperative control, amplification kinetics synchronous optimization and sequence structure differentiation design, a comparison test of homologous serum and a plasma sample is completed aiming at the plasma sample in clinical verification, the positive coincidence rate, the negative coincidence rate and the total coincidence rate are 99.49%, 86.67% and 98.57% respectively, and the positive coincidence rate, the negative coincidence rate and the total coincidence rate are both 99.49%, 86.67% and 98.57% respectively. The internal standard designed by the technology can be further expanded to the field of detection of various RNA / DNA viruses including HIV-1, and a standardized solution is provided for development of molecular diagnosis kits.

A biological sample processing device including a blood filtration module and an extraction module incorporated within a common housing. The blood filtration module has a dual filter structure. The extraction module includes a series of chambers that hold agents to effect any one or more of lysis, binding of target material to capture beads, washing, elution, and / or nucleic acid amplification. Moveable magnets are used to move the beads through the chambers to perform the extraction process. A second magnet-based device for preparing largely pure plasma samples from whole blood in the field.

The present invention discloses a method for constructing a dual-omics plasma fingerprint model and an infection diagnosis device of the dual-omics plasma fingerprint model constructed by using this method, which relates to the technical field of infection disease diagnosis. The construction method includes preprocessing plasma samples, preparing matrix materials, spotting samples and matrixes on a mass spectrometry target plate, collecting plasma metabolite fingerprints in nanoparticle-enhanced laser desorption ionization mass spectrometry, and collecting plasma protein fingerprints in organic matrix material-assisted laser desorption ionization mass spectrometry. The infection diagnosis device performs data analysis on the dual-omics plasma fingerprint map to obtain a diagnosis result, and has advantages such as high detection reproducibility, fast analysis speed, and less sample consumption, realizing high-efficiency diagnostic performance for different infection types.

The present invention provides a method of determining endometrial status using a sample (e.g., a plasma sample) from a subject, comprising: (a) performing an assay on a blood sample from a subject to determine a miRNA expression profile wherein the miRNA expression profile comprises a plurality of expression levels of miRNAs, and (b) analyzing the miRNA expression profile using a computer-based machine learning model to obtain a predicted score.

The present invention discloses a one-time injection high-efficiency microfluidic detection chip, the detection chip has a rotation center, and the detection chip includes at least one detection unit that can independently perform detection, the detection unit includes a mixed cultivation tank for providing a reaction space, and a solid reagent storage tank storing N different solid reagents is arranged in the mixed cultivation tank; the solid reagent includes a first, a second, ..., and an Nth solid reagent, all of which are coated with a protective film on the outside, and the outside of the Nth solid reagent is sequentially coated with a first protective film, a second protective film, ..., and an Nth protective film from the outside to the inside. The present invention can directly use whole blood, peripheral blood, serum, and plasma samples without sample pretreatment; it can process samples of high hematocrit / polycythemia; only one-time injection of the sample is required to automatically complete complex sample addition and reaction steps; it can reduce the overall reaction time without affecting the detection efficiency, and quickly complete blood testing.

The present invention relates to a method for determining whether an unknown blood sample is a serum sample, a citrated plasma sample, or an EDTA-treated plasma sample. The invention also relates to a method for the diagnosis and / or monitoring of a patient suffering from a hemostasis disorder.

The present disclosure deals with the biochemistry of reagents useful in the detection of ammonia in liquid samples. Specifically, the present disclosure is directed to a technical improvement of an enzyme-based test for ammonia that can be used for analysis of plasma samples taken from patients in clinical settings, among other uses. In this regard, stability of a reagent containing NAD(P)H is improved, enhancing shelf life and results in the detection of ammonia. In an exemplary reagent ammonia released as a result of NAD(P)H decay is scavenged using an enzymatic reaction to convert the ammonia using GLDH, NAD(P)H and 2-oxoglutarate, thereby forming L-glutamate, NAD(P)+ and H2O in the NAD(P)H containing reagent.

The invention discloses a detection system and method, and the system comprises a blood sample collection module which is used for collecting a plasma sample, carrying out the surface enhanced Raman scattering of the plasma sample, and obtaining a plasma component Raman spectrum signal; the Raman signal collection module is used for collecting the Raman spectrum signal, optimizing the Raman spectrum signal, converting the Raman spectrum signal into an electric signal, generating a plasma component frequency shift image according to the converted electric signal, and sending the plasma component frequency shift image to the analysis and diagnosis module; the analysis and diagnosis module is used for comparing the frequency shift image with a tumor marker image in a Raman frequency shift database so as to identify a tumor marker; and tumor characteristics are diagnosed according to the identified tumor markers. The detection system provided by the invention can efficiently and accurately obtain a cerebrospinal fluid detection result.

The invention discloses a plasma near-infrared spectrum mode recognition method for detecting latent hepatitis B. The method comprises the following steps: S1, collecting spectral data of a plasma sample to be tested in a near-infrared band; s2, acquiring multi-repetition near infrared spectrum data of each sample, and constructing a spectrum data set; s3, grouping samples of a latent hepatitis B infection group and a normal control group in the spectral data set; s4, constructing an OBI-normal control spectrum discrimination model of the plasma sample based on a classifier primitive algorithm; s5, preprocessing parameters are optimized based on the discriminant performance of the classifier; s6, constructing an optimal wavelength combination; and S7, checking the optimal model. Compared with the prior art, the plasma near infrared spectrum mode recognition method for detecting the latent hepatitis B has the advantage that a solution can be provided for developing a small special blood analyzer for detecting latent hepatitis B infection.

The present disclosure relates to an application of gene markers in multi-cancer early detection, a method for constructing an early detection model, and a detection device. In the present disclosure, low-coverage whole-genome sequencing is conducted on cell-free DNAs (cfDNAs) from a plasma sample, and according to high-throughput sequencing results, six differential features of the cfDNA fragments are analyzed for each cancer. Then the training and modeling are conducted with a convolutional neural network to allow the early detection of a plurality of cancers at a low sequencing depth. Then the training and modeling are conducted with a generalized linear model (GLM), a gradient boosting machine, a random forest model, a deep learning model, and an extreme gradient boosting model, and staking is conducted with a GLM to construct a multi-feature algorithm, to allow the tissue-of-origin-based detection of cancers.

The application discloses polypeptide markers based on autoantibodies and application thereof in early lung cancer diagnosis, and relates to the technical field of biological detection. The application finds that there are 143 polypeptide probes with significant signal differences between a lung adenocarcinoma group in early stage and a healthy population group through research and analysis of plasma samples of the two groups, and further screens 14 polypeptide probes that can produce more stable signal differences between the two groups. Through attempts of various machine learning methods, it is found that a classification model can be established by taking the signal value accumulation of the 14 polypeptide probes as an index for model construction, thereby providing a path for effective diagnosis of early lung adenocarcinoma.

The invention discloses a turbidity evaluation processing method and system for a blood separation plasma sample and a storage medium, and the method comprises the steps: firstly, processing a first image containing target cells to obtain a second image, and intercepting a third image only containing the target cells from the second image; therefore, errors caused by subsequent identification of the attribute information of the target cell due to factors such as the surrounding environment of the target cell are reduced; inputting the third image into an image recognition model trained through operations such as a convolutional layer, a pooling layer and an activation function, detecting, recognizing and outputting five-level associated feature information of the target cell, performing associated recognition on the five-level associated feature information and a preset contrast feature information table, and outputting attribute information of the target cell; by guaranteeing the recognition precision of the sample image, the turbidity of the plasma sample is evaluated and monitored.

The disclosure discloses a method for treating a plasma sample containing (7aS,2′S)-2-oxo-clopidogrel and a method for determining the same, which belongs to the technical field of pharmaceutical analysis and solves the problem in the prior art that there is not yet a method for determining the concentration of (7aS,2′S)-2-oxo-clopidogrel in plasma. The method for treating a plasma sample containing (7aS,2′S)-2-oxo-clopidogrel comprises: taking whole blood containing (7aS,2′S)-2-oxo-clopidogrel, adding a reducing agent solution and collecting plasma. The method for determining (7aS,2′S)-2-oxo-clopidogrel in plasma according to the disclosure uses the treatment method as described above to treat a sample to be determined, and includes the following steps: S1. Whole blood treatment: taking whole blood, adding a reducing agent solution, centrifuging, and collecting plasma; S2. Plasma sample pre-treatment: adding a protein precipitant and an internal standard working solution to the plasma, vortexing and then centrifuging, and taking the supernatant; S3. LC / MS / MS determination. The method of the disclosure is simple, easy to operate, and has good stability, specificity and sensitivity, and accurate determination results.

A system for collecting menstrual blood and vaginal secretions for diagnostic and health monitoring purposes, and more particularly, to a system for providing absorbent materials, such as female sanitary pads and urinal pads, with a strip or patch for collecting bodily fluids, providing a container comprising a desiccant for transporting and storing the collected sample to a laboratory, dried menstrual blood samples (DMS), dried menstrual blood plasma samples (DMPS), dried blood spots (DBS), and / or dried blood plasma spots (DPS) are analyzed in a laboratory, or some of the containers without desiccant can maintain sufficient hydration to maintain the collected cells intact, for analysis using methods such as DNA testing, slide-based analysis, or cell culture, for example, for use in the field of laboratory analysis of dried menstrual blood samples (DMS), dried menstrual blood plasma samples (DMPS), dried blood spots (DBS), and / or dried blood plasma spots (DPS), or some of the containers without desiccant can maintain sufficient hydration to maintain the integrity of the collected cells. Various collection strip structures are provided that can be used for menstrual blood and vaginal secretions and for collecting and / or separating venous blood and capillary blood, as well as functional pad design elements to aid in sample collection, retention of collection strips, and to facilitate high speed manufacturing of pads.

The invention discloses an aptamer-mediated EXPARs-molecular beacon fluorescent biosensor as well as a preparation method and application of the aptamer-mediated EXPARs-molecular beacon fluorescent biosensor. The construction and detection process of the sensor comprises three key steps: protein binding aptamer, exponential isothermal amplification (EXPAR) and molecular beacon fluorescence resonance energy transfer (FRET). Through the ingenious design of the EXPAR system, the system realizes triple signal amplification, the detection sensitivity is remarkably improved, and Abeta42 and Abeta40 amyloid proteins as low as 100fM level can be detected. Besides, based on the sequence specificity of the aptamer and the highly specific design of each nucleic acid sequence involved in the detection system, the method can be used for simultaneously detecting the Abeta42 amyloid protein and the Abeta40 amyloid protein or other substances in the same system (such as a plasma sample), so that the detection efficiency is improved.

Devices, assemblies, and kits are disclosed for separating and / or metering a plasma sample from a patient's liquid test sample. Also disclosed are methods of producing and using same.

The utility model relates to the technical field of medical instruments, in particular to a sample placing tray for a plasma electrolyte detector, which comprises a base, the plasma electrolyte detector and a tray, the plasma electrolyte detector and the tray are placed on the base, a driving disc is mounted in the tray, a clamping component for placing a test tube is arranged on the driving disc, and the clamping component is arranged on the base. A first rack is slidably connected into the material disc, an ejector rod is connected to the top of the first rack and penetrates through the driving disc to make contact with the clamping assembly, a gear is rotatably connected into the material disc, a pressing plate is slidably connected to the outer ring of the material disc, the part, located in the material disc, of the pressing plate is connected with a second rack, and the first rack and the second rack are located on the two sides of the gear correspondingly and engaged with the gear. And a second reset spring is arranged between the second rack and the charging tray. Through cooperation of a clamping plate, a guide rod and a first reset spring in the clamping assembly, the plasma sample test tube is stably clamped, the clamping device automatically adapts to test tubes of different sizes through the elastic force of the spring, and the clamping compatibility and flexibility are improved.